NASDAQ · Biotechnology · USD
Neumora Therapeutics, Inc. (NMRA) Stock Analysis
Neumora Therapeutics, Inc. (NMRA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NMRA Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.47
- Previous Close
- $0.47
- Day's Range
- 0.41–0.48
- 52-Week Range
- 0.32–3.65
- Volume
- 1.58M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.98
Valuation
- Market Cap
- $78.16M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.23
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$236.93M
- Shares Outstanding
- 187.90M
- 1-Year Return
- −76.89%
Dividend and dates
- Earnings Date
- November 5, 2026estimated
- Avg Volume
- 1.40M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NMRA closed at $0.42, −76.89% over 1 year.
Neumora Therapeutics, Inc. (NMRA) has a market capitalization of $78.16M.
In fiscal 2025, NMRA reported revenue of $0.00.
NMRA Stock Return by Calendar Year
Neumora Therapeutics, Inc. (NMRA) return since Sep 2023: what $10,000 became
- 1 year
- $10,000 $2,311
- −76.89%
- 3 years
- $10,000 $397
- −96.03%
- Since Sep 2023
- $10,000 $245
- −97.55%
If you had invested $10,000 in Neumora Therapeutics, Inc. (NMRA) at the close on September 14, 2023, the earliest close on record here, it would have been worth $245 at the close on October 21, 2026: −97.55% in total, −69.76% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −76.76% |
| 2025 | −83.11% |
| 2024 | −37.83% |
| 2023 (partial year) | +0.29% |
As of October 21, 2026.
NMRA Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$236.93M | — |
| 2024 | $0.00 | −$243.79M | — |
| 2023 | $0.00 | −$235.93M | — |
| 2022 | $0.00 | −$130.90M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$241.16M | −$236.93M | — |
| 2024 | $0.00 | — | −$263.46M | −$243.79M | — |
| 2023 | $0.00 | — | −$252.10M | −$235.93M | — |
| 2022 | $0.00 | — | −$135.87M | −$130.90M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Biotech Options Buzz: UTHR, NMRA, EWTX
YahooNeumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate
BenzingaNeumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B